(Q44817262)

6 December 2017

1 reference

title

Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype (English)

1 reference

6 December 2017

H Bonkhoff

1

1 reference

6 December 2017

T Fixemer

series ordinal

2

1 reference

6 December 2017

language of work or name

German

0 references

publication date

1 July 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

43

1 reference

6 December 2017

issue

7

1 reference

6 December 2017

page(s)

836-842

1 reference

Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?

6 December 2017

cites work

1 reference

12 December 2020

Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.

1 reference

12 December 2020

Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy

1 reference

12 December 2020

Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

1 reference

12 December 2020

Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis

1 reference

12 December 2020

Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model

1 reference

12 December 2020

Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer

1 reference

12 December 2020

The proliferative function of basal cells in the normal and hyperplastic human prostate

1 reference

12 December 2020

Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells

1 reference

12 December 2020

Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma

1 reference

12 December 2020

Morphogenetic concepts of normal and abnormal growth in the human prostate

1 reference

12 December 2020

Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.

1 reference

12 December 2020

Simultaneous detection of DNA fragmentation (apoptosis), cell proliferation (MIB-1), and phenotype markers in routinely processed tissue sections

1 reference

12 December 2020

Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.

1 reference

12 December 2020

Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate

1 reference

12 December 2020

Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients

1 reference

12 December 2020

Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer

1 reference

12 December 2020

Neuroendocrine serum tumour markers in hormone-resistant prostate cancer

1 reference

12 December 2020

Neuroendocrine differentiation in prostatic malignancy

1 reference

12 December 2020

Androgen receptor gene and hormonal therapy failure of prostate cancer

1 reference

12 December 2020

Serum chromogranin A in monitoring metastatic prostate cancer patients

1 reference

12 December 2020

Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers

1 reference

12 December 2020

Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.

1 reference

12 December 2020

Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate

1 reference

12 December 2020

Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer

1 reference

12 December 2020

Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate

1 reference

12 December 2020

Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas

1 reference

12 December 2020

Circulating neuroendocrine markers in patients with prostate carcinoma

1 reference

12 December 2020

10.1007/S00120-004-0559-9

Identifiers

DOI

1 reference

release_d5vnit6evvfuhnvhlcblceu3g4

6 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d5vnit6evvfuhnvhlcblceu3g4

24 November 2022

mapped directly with Wikidata item

1 reference